[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641046":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":36,"responsibleParty":81,"collaborators":25,"id":85,"slug":25,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":25,"enrollmentInfo":93,"targetDuration":25,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":25,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},{"fullName":5,"class":6},"Spanish Society of Cardiology","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CSP ON","ACTIVE_COMPARATOR","Continuous Conduction System Pacing (CSP)",[13],"Device: Pacemaker implant",{"label":15,"type":16,"description":17,"interventionNames":18},"CSP OFF","PLACEBO_COMPARATOR","Non active Conduction System Pacing (CSP)",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","Pacemaker implant","All patients will receive a ventricular lead in the conduction system (HBP or LBBAP) using conventional implant techniques described elsewhere. The pacemaker device and leads should be implanted according to the physician's manual provided with the devices. Only locally approved Medtronic PM generators with MVP algorithms will be used during the study.\n\nInvestigators will use the Medtronic Select Secure 3830 lead for CSP. Acceptable LBBAP threshold should be \\\u003C2,5V@0,5ms. Other commercially available stylet driven leads may be used as bail-out strategy only when CSP cannot be achieved with the 3830 lead at the implanting physician discretion.\n\nDuring the implant procedure lead impedances, pacing and sensing parameters will be measured using a pacing system analyzer (PSA).\n\nIt is strongly encouraged the designation of a single and experienced CSP implanting physician at each center.",[15,9],null,[27,33],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Óscar Cano, MD, PhD","CONTACT","+34 961244000","440079","cano_osc@gva.es",{"name":34,"role":29,"phone":30,"phoneExt":35,"email":25},"Bernabé López, MD","412713",[37,55,70],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Hospital Universitario Virgen de las Nieves","RECRUITING","Granada","Andalusia","18014","Spain",{"type":45,"coordinates":46},"Point",[47,48],-3.60667,37.18817,{"lat":48,"lon":47},[51],{"name":52,"role":29,"phone":53,"phoneExt":25,"email":54},"Manuel Molina, MD","+34 958020000","manuel.molina.lerma@gmail.com",{"facility":56,"status":39,"city":57,"state":58,"zip":59,"country":43,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Hospital Clínico Universitario Lozano Blesa","Zaragoza","Aragon","50009",{"type":45,"coordinates":61},[62,63],-0.87734,41.65606,{"lat":63,"lon":62},[66],{"name":67,"role":29,"phone":68,"phoneExt":25,"email":69},"Javier Ramos, MD","+34 976765700","javierramosmaqueda7@gmail.com",{"facility":71,"status":39,"city":72,"state":72,"zip":73,"country":43,"cosmosGeoPoint":74,"geoPoint":78,"contacts":79},"Hospital Universitari i Politècnic La Fe","Valencia","46026",{"type":45,"coordinates":75},[76,77],-0.37966,39.47391,{"lat":77,"lon":76},[80],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},{"type":82,"investigatorFullName":83,"investigatorTitle":84,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Óscar Cano Pérez","Principal Investigator","100641046",false,"NCT07585799","Permanent Conduction System Pacing Versus Atrioventricular Management for Patients With Wide QRS and Patent AV Conduction","MORE-CSP","Inclusion Criteria:\n\n* age \\> 18 years\n* Any indication for cardiac pacing with an expected VP burden ≤ 10% after 1- month run-in period\n* Baseline wide QRS (≥150 ms) with normal PR or QRS ≥ 130 ms + PR≥230 ms\n* LVEF≥50%\n* Confirmed CSP criteria\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Pregnant woman\n* Permanent or long-lasting atrial fibrillation\n* Previous PM\u002FICD\n* Unstable angina, acute Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG), Percutaneous Coronary Angioplasty (PCI), surgical valve repair or replacement within 90 days prior enrollment\n* Moderate-severe valvular heart disease (unrepaired)\n* Already included in another clinical study that could confound the results of the present study\n* Infiltrative disease or any other genetically or acquired primary myocardial disease\n* Life expectancy \\\u003C 2 years\n* LVEF \\\u003C50%","ALL","18 Years",{"count":94,"type":95},120,"ESTIMATED","INTERVENTIONAL",[98],"NA","Intraventricular conduction delay alone or in combination with AV conduction delay is associated with a dyssynchronous activation of the ventricles and may result in LV function impairment.\n\nConduction system pacing can restore physiologic ventricular activation in the presence of intraventricular and atrioventricular conduction delays.\n\nPatients with intraventricular conduction delay alone or in combination with AV conduction delay who have a permanent pacemaker indication due to intermittent bradycardia and have predominantly intact AV conduction may benefit from continuous CSP.",[101],"Bradycardia","2026-05-13",{"date":104,"type":105},"2026-05-15","ACTUAL",{"date":107,"type":105},"2025-07-29",{"date":109,"type":95},"2029-01-15",{"name":83,"class":6},3]